Q3 2022 Results

Company overview Financial review 2022 priorities Appendix References 1 GROWTH KesimptaⓇ strong sales growth mainly driven by US launch momentum YCE Z K Kesimpta L Sales evolution USD m, % cc Ex-US US +172% Launch acceleration continues¹ 7 289 239 195 147 109 66 TRX +131% NBRX +47% vs. market -20% B-cell NBRx share -30% ■ Adding ~100 new writers/month Fast initiation within 5 days for 80% patients² >27k patients treated WW Benefit/risk profile (new data) 50 ☐ New 4-year data in recently diagnosed and treatment naive Kesimpta treated patients (subgroup) support use in early stages of RMS disease³ Q1/21 Q2/21 Q3/21 Q4/21 Q1/22 Q2/22 Q3/22 WW-worldwide TRX - Total Prescriptions NBRX - New to brand Prescription DMT Disease Modifying Therapy 1. Refers to US unless otherwise stated 2. Time to bridge. Data on file 3. Data from ALITHIOS study. Analysis compares continuous treatment with Kesimpta and later switch from teriflunomide in recently diagnosed treatment naive patients (subgroup). Gartner J et al. Longer-term Safety and Efficacy of Ofatumumab in Recently Diagnosed and Treatment Naïve Patients is Consistent with the Overall Population in the ALITHIOS Open-Label Extension Study. Poster presented at ECTRIMS 2022. P052. 11 Investor Relations | Q3 2022 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation